Medical School

Tumour Immunology Group

The Tumour Immunology Group (TIG) is a dynamic collaboration of 25 scientists (including seven postdoctoral scientists), clinicians, and students with a broad range of research expertise.

TIG is internationally recognised for its achievements and expertise in the field of tumour immunobiology.  Its research focuses on the development of effective therapies for the treatment and prevention of mesothelioma, and the identification of novel biomarkers for early detection of this disease.

TIG is part of the National Centre for Asbestos Related Diseases (NCARD) and is based at Sir Charles Gairdner Hospital within the UWA School of Medicine and Pharmacology.


The National Centre for Asbestos Related Diseases (NCARD) is a national research centre funded by the National Health & Medical Research Council (NHMRC) through its prestigious Centre for Research Excellence programme.

  • Enables and encourages collaboration by researchers
  • Provides a national and strategic focus for research into asbestos related diseases and cancers
  • Builds on Australia‚Äôs existing research expertise
  • Encourages strong organisational linkages
  • Ensures our research is systematic and complementary to existing research efforts


  • Asbestos-induced cancers such as mesothelioma kill more than 20,000 people worldwide per year and 500 per year in Australia
  • Australia has the highest incidence of malignant mesothelioma in the world
  • Mesothelioma is particularly common in Western Australia because of the history of mining crocidolite asbestos (blue asbestos) in Wittenoom.
  • There is currently no curative treatment for this aggressive cancer
  • Patients have a median survival of just 9 months after diagnosis
  • There is typically a long latency between asbestos exposure and disease diagnosis (often up to 40 years) that makes identification and prognosis difficult
  • We need a better understanding of the biology of this disease
  • We need to improve and develop better therapies